We recently demonstrated a beneficial action of a TGF-β signalling inhibitor (SB-431542) administered during the acute phase of experimental Chagas disease, indicating that inhibition of TGF-β-induced activity could represent a new therapeutic action for acute and chronic Chagas disease treatment [4]. This evidence concerns the gene TGFB1 and Chagas disease.